Business Context and Reporting Period
This Form 8-K filing by Bio-Rad Laboratories, Inc. (BIO) was submitted on November 8, 2022. The report discloses an update regarding the Company's share repurchase program under Item 7.01 (Regulation FD Disclosure).
Key Financial Metrics
The filing focuses exclusively on capital allocation activities related to share buybacks. No revenue, profit, cash flow, or debt metrics are reported in this specific document.
- Repurchase Authorization: Up to $650.0 million authorized by the Board (approved in 2017, 2020, and 2022).
- Remaining Authorization (as of Sept 30, 2022): $298.1 million.
- Quarter-to-Date Repurchases (as of Nov 8, 2022): $67.1 million.
- Shares Acquired: 182,228 shares of Class A Common Stock.
- Average Purchase Price: $368.40 per share (inclusive of commissions).
- Remaining Authorization (as of Nov 8, 2022): $231.0 million.
Material Changes
Between September 30, 2022, and November 8, 2022, the Company reduced its available share repurchase authorization by $67.1 million through open market purchases. The filing does not provide comparative financial data for prior periods regarding revenue or earnings.
Guidance, Outlook, and Risks
Management Commentary: Repurchases are executed at management's discretion and may be suspended or discontinued at any time. The program has no time limit. Acquired shares will be held for general corporate purposes, including supporting employee stock plans, funding acquisitions, and minimizing dilution.
Risks and Contingencies: The filing notes that the information provided is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the total remaining authorization of $231.0 million against subsequent 8-K filings or quarterly reports.
- Confirm the average purchase price of $368.40 aligns with market trading data for the period.
- Review the Company's most recent 10-Q or 10-K for comprehensive revenue, profit, and liquidity metrics not included in this 8-K.
- Monitor future announcements for any suspension or acceleration of the share repurchase program.